[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$650mm
$650mm sees increased mentions and creator activity, with investors eyeing $RARE amidst financial discussions. However, delays and dilution risks are causing some concern.
About $650mm
This topic refers to discussions and analysis surrounding the financial performance and market activity of a company or asset with a $650mm revenue.
Insights #
- $650mm creators is up XXX% from the previous month.
- $650mm mentions is up XXXXX% from the previous month.
- $650mm Creators hit a high of X for the day
- $650mm Creators hit an all time of X for the day
- $650mm Mentions hit a high of X for the day
- $650mm Mentions hit an all time of X for the day
Engagements: XX #
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1 Month: XXXXX -XX%
1-Year High: XXXXX on 2025-05-05
1-Year Low: X on 2025-06-22
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X +75%
1 Month: XX +86%
1-Year High: X on 2025-07-19
1-Year Low: X on 2025-04-27
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $650mm in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1 Week: X +33%
1 Month: X +200%
1-Year High: X on 2025-07-19
1-Year Low: X on 2025-04-27
Top assets mentioned In the posts about $650mm in the last XX hours
SuperRare (RARE) SuperRare (RARE) Core Scientific, Inc. Common Stock (CORZ)
Top topics mentioned In the posts about $650mm in the last XX hours
$rare, investment, ipo, germany, drugs, $nnnn, $414mm, $550mm, $450mm, superrare, $coz, $3b, rating agency, $corz, reit
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@LBR_ZA I certainly know their worth. Great place to start adding with CCs. Not as dramatic but $RARE is another to keep your eye on with $650mm annual revenue $450mm cash clean record with the FDA until this recent delay. Investors are worried about dilution now with the delay"
@ilzizzo on X 2025-07-20 03:10:02 UTC 1727 followers, XX engagements
"$RARE remains a moderate risk high-reward investment. The Orbit studys adherence to its 18-month timeline and their clean FDA approval record (4-for-4 no CRLs) strengthen its long-term potential in the rare disease space. UX111s delay is a manageable hurdle anticipated approval in 2026 - They have roughly $550mm in cash with $414mm burn and projected to do $650mm in revenue this year. Cash burn and potential dilution risk warrant caution. For risk-tolerant investors with a 24+ month horizon with a target of $65$85 by end-2026 if pipeline milestones are met. A Hold or Watch stance is prudent"
@ilzizzo on X 2025-07-17 05:36:46 UTC 1732 followers, XXX engagements